ECKERT+ZIEGLERINH O.N. overview

EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler SE's Communication Channels 03.02.2025 / 13:23 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release IT Incident Affects Eckert & Ziegler SE's Communication Channels Berlin, 03 February 2025. Due to an unexpected IT incident, Eckert & Ziegler is currently unable to receive emails or phone calls. We understand the inconvenience this may cause...

EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Preliminary Results Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase in Sales and Adjusted EBIT 27-Jan-2025 / 18:55 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Financial Year 2024 (preliminary): Sales of around EUR 295 million (previous year:...

EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Alliance Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture 14-Jan-2025 / 17:03 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Berlin, 14 January 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi...

EQS-News: Eckert & Ziegler SE / Key word(s): Alliance/Incoming Orders Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement 13.01.2025 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, Germany and Sydney, Australia, 13. January 2025. Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid...

EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Admission/Market Launch Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW 13.12.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 13 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68 Ge/...

EQS-News: Eckert & Ziegler SE / Key word(s): Incoming Orders/Alliance Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments 05.12.2024 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 5 December 2024. Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, and Ariceum Therapeutics...

EQS-News: Eckert & Ziegler SE / Key word(s): Personnel Eckert & Ziegler: Changes in the Executive Board and Supervisory Board 03.12.2024 / 14:29 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 3 December 2024. The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment. Dr. Mann who holds a doctorate in...

EQS-News: Eckert & Ziegler SE / Key word(s): Product Launch Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply 02.12.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 02 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) today celebrates the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. This milestone marks a major success...